Antimicrobial Effect and Cytocompatibility After Using Different Decontamination Methods on Titanium Implant Surfaces: An In Vitro Study.

Aim: To evaluate in vitro the antibacterial efficacy and cytocompatibility of different implant-decontamination methods, using both 2D and 3D peri-implant mucosa models.

Methods: Four decontamination methods [chlorhexidine (CHX), electrolytic treatment (GS), curcumin (CUR), xanthohumol (XN)] were compared in four independent experiments, three with a 2D peri-implant mucosa model on titanium surfaces and another on a 3D peri-implant mucosa model. These decontamination procedures were tested for their antibacterial effect using a multispecies biofilm model with Streptococcus oralis, Actinomyces naeslundii, Veillonella dispar, and Porphyromonas gingivalis for 24 h.

Bilirubin Removal With Therapeutic Plasma Exchange Or Molecular Adsorbent Recirculating System (MARS®) As Treatment For Cholemic Nephropathy In Patients With Cirrhosis and ACLF: A case series.

Introduction: Cholemic nephropathy is an overlooked cause of acute kidney injury (AKI) in patients with advanced cirrhosis and high bilirubin plasma levels (usually above 20mg/dl), due to bilirubin and bile acid deposition in the kidneys. Those deposits have been hypothesized to cause tubular injury. It has no standardized diagnostic criteria or therapeutic strategies.

Incidence and Risk Factors of Peri-Implantitis Over Time-A Prospective Cohort Study.

Aim: This prospective cohort study aimed to evaluate the incidence and risk/protective factors of peri-implantitis over time.

Methods: A university-representative cohort was evaluated at baseline and after a mean follow-up time of 3.9 years.

Incidence, Risk Factors, and Outcomes of BK Hemorrhagic Cystitis in Hematopoietic Stem Cell Transplantation From HLA-Matched and Haploidentical Donors With Post-Transplant Cyclophosphamide.

BK hemorrhagic cystitis (BK-HC) is a common complication following hematopoietic stem cell transplantation (HSCT), particularly when posttransplant cyclophosphamide (PTCy) is used as graft-versus-host disease (GVHD) prophylaxis. However, comparative studies of BK-HC incidence in matched sibling donors (MSD) and unrelated donors (MUD) often include small haploidentical (HAPLO) donor cohorts and usually lack detailed information on disease evolution, coinfections, management and impact on outcomes. This study aimed to evaluate the incidence, risk factors, and outcomes in patients with hematologic malignancies undergoing HSCT from MSD, MUD, HAPLO donors using PTCy as GVHD prophylaxis.